New trial aims to stop CMV eye inflammation from returning

NCT ID NCT07513623

Not yet recruiting Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This study tests whether oral valganciclovir or ganciclovir eye drops can reduce the virus causing eye inflammation and prevent flare-ups. About 117 adults with CMV anterior uveitis will receive either antiviral treatment or placebo for 7 days, then some continue for 12 months. The goal is to find a better way to control the infection and keep the disease from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Valganciclovir (oral) and ganciclovir (eye drops)
What this could lead to: If successful, this could provide effective antiviral strategies to control CMV eye inflammation and reduce the risk of it coming back.
What could go wrong: This is an early phase 2 trial with a small number of participants. The treatments may not work better than placebo, and side effects from antiviral drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTERIOR UVEITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anterior uveitis cytomegalovirus infection infectious anterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTERIOR UVEITIS CMV INFECTION CYTOMEGALOVIRUS (CMV) INFECTIOUS UVEITIS

Contacts and locations

Locations

Chang Gung University

Taoyuan, Taiwan
Chiang Mai University

Chiang Mai, Thailand
Chulalongkorn University

Bangkok, Thailand
Khon Kaen University

Khon Kaen, Thailand
Proctor Foundation, University of California San Francisco

San Francisco, California, 94158, United States
Stein Eye Institute, University of California Los Angeles

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.